Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04357756
Registration number
NCT04357756
Ethics application status
Date submitted
17/04/2020
Date registered
22/04/2020
Date last updated
13/09/2023
Titles & IDs
Public title
A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
Query!
Scientific title
A First-in-human (FIH), Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
Query!
Secondary ID [1]
0
0
YH001002
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Advanced Solid Tumor
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - YH001
Treatment: Drugs - Toripalimab
Experimental: YH001 combined with Toripalimab - All the patients will receive YH001 intravenously as single agent for 21 days followed by combination phase.
Treatment: Drugs: YH001
YH001 will be administered intravenously every three weeks (Q3W) for 15 weeks (5 cycles) at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F and Dose G.
Treatment: Drugs: Toripalimab
Toripalimab will be administered by intravenously (Q3W) by the fixed dose of 240 mg from the 2nd cycle to 5th cycle.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of participants with adverse events and serious adverse events
Query!
Assessment method [1]
0
0
The safety profile of YH001 will be assessed by monitoring the adverse events (AE) per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0
Query!
Timepoint [1]
0
0
From screening up to 1 year
Query!
Primary outcome [2]
0
0
Maximum tolerated dose (MTD)
Query!
Assessment method [2]
0
0
MTD is defined as the highest dose level at which no more than 1 out of 6 subjects experiences a DLT during the first cycle
Query!
Timepoint [2]
0
0
During Cycle 1 (each cycle is 21 days)
Query!
Primary outcome [3]
0
0
Dose-limiting toxicities (DLT)
Query!
Assessment method [3]
0
0
DLT is defined as a toxicity (adverse event at least possibly related to YH001) occurring during the DLT observation period (the initial 21 days) both in run-in phase of YH001 as single agent and in combination phase of YH001 in combination with Toripalimab
Query!
Timepoint [3]
0
0
During Cycle 1 (each cycle is 21 days)
Query!
Secondary outcome [1]
0
0
Area under the serum concentration versus time curve within one dosing interval (AUCtau)
Query!
Assessment method [1]
0
0
To determine the PK profile of YH001 alone and in combination with Toripalimab
Query!
Timepoint [1]
0
0
Up to 1 year
Query!
Secondary outcome [2]
0
0
Steady state AUC
Query!
Assessment method [2]
0
0
To determine the PK profile of YH001 alone and in combination with Toripalimab
Query!
Timepoint [2]
0
0
Up to 1 year
Query!
Secondary outcome [3]
0
0
Maximum serum concentration (Cmax)
Query!
Assessment method [3]
0
0
To determine the PK profile of YH001 alone and in combination with Toripalimab
Query!
Timepoint [3]
0
0
Up to 1 year
Query!
Secondary outcome [4]
0
0
Trough concentration before the next dose is administered (Ctrough)
Query!
Assessment method [4]
0
0
To determine the PK profile of YH001 alone and in combination with Toripalimab
Query!
Timepoint [4]
0
0
Up to 1 year
Query!
Secondary outcome [5]
0
0
Time to reach maximum serum concentration (Tmax)
Query!
Assessment method [5]
0
0
To determine the PK profile of YH001 alone and in combination with Toripalimab
Query!
Timepoint [5]
0
0
Up to 1 year
Query!
Secondary outcome [6]
0
0
Clearance (CL)
Query!
Assessment method [6]
0
0
To determine the PK profile of YH001 alone and in combination with Toripalimab
Query!
Timepoint [6]
0
0
Up to 1 year
Query!
Secondary outcome [7]
0
0
Volume of distribution (Vd)
Query!
Assessment method [7]
0
0
To determine the PK profile of YH001 alone and in combination with Toripalimab
Query!
Timepoint [7]
0
0
Up to 1 year
Query!
Secondary outcome [8]
0
0
Terminal half-life (T1/2)
Query!
Assessment method [8]
0
0
To determine the PK profile of YH001 alone and in combination with Toripalimab
Query!
Timepoint [8]
0
0
Up to 1 year
Query!
Secondary outcome [9]
0
0
Dose proportionality
Query!
Assessment method [9]
0
0
To determine the PK profile of YH001 alone and in combination with Toripalimab
Query!
Timepoint [9]
0
0
Up to 1 year
Query!
Secondary outcome [10]
0
0
Incidence of anti-drug antibodies (ADAs)
Query!
Assessment method [10]
0
0
To assess the immunogenicity of YH001 in combination with Toripalimab
Query!
Timepoint [10]
0
0
Up to 1 year
Query!
Secondary outcome [11]
0
0
Incidence of neutralizing antibodies (NAbs)
Query!
Assessment method [11]
0
0
To assess the immunogenicity of YH001 in combination with Toripalimab
Query!
Timepoint [11]
0
0
Up to 1 year
Query!
Secondary outcome [12]
0
0
Objective response rate (ORR)
Query!
Assessment method [12]
0
0
To assess the preliminary antitumor activity of YH001 in combination with Toripalimab
Query!
Timepoint [12]
0
0
Up to 1 year
Query!
Secondary outcome [13]
0
0
Duration of response (DOR)
Query!
Assessment method [13]
0
0
To assess the preliminary antitumor activity of YH001 in combination with Toripalimab
Query!
Timepoint [13]
0
0
Up to 1 year
Query!
Secondary outcome [14]
0
0
Time to response (TTR)
Query!
Assessment method [14]
0
0
To assess the preliminary antitumor activity of YH001 in combination with Toripalimab
Query!
Timepoint [14]
0
0
Up to 1 year
Query!
Secondary outcome [15]
0
0
Progression free survival (PFS)
Query!
Assessment method [15]
0
0
To assess the preliminary antitumor activity of YH001 in combination with Toripalimab
Query!
Timepoint [15]
0
0
Up to 1 year
Query!
Secondary outcome [16]
0
0
Overall survival (OS)
Query!
Assessment method [16]
0
0
To assess the preliminary antitumor activity of YH001 in combination with Toripalimab
Query!
Timepoint [16]
0
0
Up to 1 year
Query!
Secondary outcome [17]
0
0
Disease control rate (DCR)
Query!
Assessment method [17]
0
0
To assess the preliminary antitumor activity of YH001 in combination with Toripalimab
Query!
Timepoint [17]
0
0
Up to 1 year
Query!
Secondary outcome [18]
0
0
Duration of disease control (DDC)
Query!
Assessment method [18]
0
0
To assess the preliminary antitumor activity of YH001 in combination with Toripalimab
Query!
Timepoint [18]
0
0
Up to 1 year
Query!
Eligibility
Key inclusion criteria
- Male or female, aged = 18 years
- Have advanced histologically or cytologically confirmed solid tumor
- Have progressed on after treatment with standard therapies or intolerant of standard
care
- At least 1 unidimensional measurable target lesion per RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1
- Have life expectancy of at least 12 weeks based on investigator's judgement
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Treated with any investigational drug within 4 weeks prior to the fist dose of study
drug
- Received any anticancer therapy less than 28 days prior to the first administration of
study drug or within 5 half-lives of the therapy agent, whichever is shorter. Prior
palliative radiotherapy to bone metastases = 2 weeks prior to the first dose of YH001
is acceptable
- Subjects with prior anti-CTLA-4 checkpoint inhibitors should be excluded
- Subjects with prior PD-1/L1 treatment intolerate to PD-1/L1 therapy should be excluded
- Subjects with a history of = Grade 3 immune-related adverse events (AEs) resulted from
previous immunotherapy or an AE of any grade that resulted in discontinuation of prior
immunotherapy
- Subjects with a history of = Grade 2 pneumonitis resulted from previous immunotherapy
or with a SpO2 by pulse oximetry < 92% at the screening
- Subjects requiring systemic treatment with corticosteroids (>10 mg/day prednisone or
equivalent) or other immunosuppressive medications within 21 days before the planned
first dose of study drug or has need to be treated while on trial. Inhaled or topical
steroids, and adrenal replacement steroid doses = 10 mg daily prednisone equivalent
are permitted in the absence of active autoimmune disease. Ophthalmologic, nasal and
intra-articular injections of steroids are allowed
- Subjects with concomitant active autoimmune disease, history of autoimmune disease
requiring systemic treatment, or history of autoimmune disease within the two years
prior to study entry. Exceptions are subjects with vitiligo, resolved childhood
asthma/atopy, type I diabetes mellitus or hypothyroidism which can be managed by
replacement therapy
- Primary central nervous system (CNS) malignancies or symptomatic CNS metastases. But
subjects with asymptomatic CNS metastases might be eligible if they have no clinical
evidence of progression since completion of CNS-directed therapy, minimum 4 weeks
between completion of radiotherapy and the first dose of YH001 and are currently not
receiving corticosteroids
- QTc > 450 ms at baseline; no concomitant medications that would prolong the QT
interval; no family history of long QT syndrome
- Continuance of toxicities due to prior radiotherapy or chemotherapy agents that have
not recovered to = Grade 1 per CTCAE v5.0, except alopecia, < Grade 2 sensory
neuropathy
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
21/04/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
19/10/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
29
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Blacktown Hospital, Blacktown Cancer and Haematology Centre - Blacktown
Query!
Recruitment hospital [2]
0
0
St George Private Hospital - Kogarah
Query!
Recruitment hospital [3]
0
0
Peninsula & South Eastern Haematology and Oncology Group - Frankston
Query!
Recruitment postcode(s) [1]
0
0
2148 - Blacktown
Query!
Recruitment postcode(s) [2]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [3]
0
0
3199 - Frankston
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Eucure (Beijing) Biopharma Co., Ltd
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is an open-label, dose-escalation study of YH001 administered intravenously (IV) in
combination with Toripalimab. The study is designed to determine the safety, tolerability and
maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of YH001 when administered in
combination with Toripalimab to subjects with advanced solid tumors.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04357756
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04357756
Download to PDF